- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00052000
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
February 28, 2007 updated by: Millennium Pharmaceuticals, Inc.
A Phase 1 Single Ascending Dose Trial of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans.
The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects associated with taking the drug.
This study will also evaluate how MLN2704 is taken up (absorbed), broken down (metabolized) and eliminated (excreted) by the body.
This process is called pharmacokinetic analysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1 open-label dose-escalating trial designed to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics of a single dose of MLN2704 in subjects with metastatic androgen-independent prostate cancer.
Study Type
Interventional
Enrollment
29
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- The Sidney Kimmel Comprehensive Cancer Center @ Johns Hopkins
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria
Each subject must meet the following inclusion criteria to be eligible for enrollment in the study:
- Histologic diagnosis (recent or remote) of prostate adenocarcinoma
Progressive prostate cancer on physical exam, imaging studies and/or rising PSA, as defined by the presence of one or more of the following:
- Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or X-ray and CT scan or MRI)
- Progressive bone metastasis (presence of new lesion(s) on a bone scan)
- Progressive PSA levels despite castrate levels of testosterone
- Patients who have received an anti-androgen must have shown progression of disease off of the anti-androgen prior to enrollment
- Failed hormonal therapy (including anti-androgen withdrawal therapy, as appropriate)
- LHRH (Luteinizing Hormone-Releasing Hormone)analog therapy:
- If subject is being treated with LHRH analog therapy at the time of screening the therapy must be maintained for the duration of the trial.
- If subject discontinued LHRH therapy prior to screening, the therapy must be discontinued ≥10 weeks prior to enrollment for 1 month depot preparations, 24 weeks for 3 month depot preparations, and 32 weeks for 4 month depot preparations.
- Agree to use an effective method of barrier contraception. Effective method of barrier contraception includes a condom with spermicidal jelly, a diaphragm with spermicidal jelly, or abstinence.
Exclusion Criteria
Subjects meeting any of the following exclusion criteria are not to be enrolled in the study:
- Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of enrollment
- Use of PC-SPES (herbal supplement) within 4 weeks of enrollment
- Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of enrollment
- Use of anti-androgen therapy (e.g., flutamide, bicalutamide, nilutamide) within 6 weeks of enrollment
- Prior monoclonal antibody administration, including Prostacint®
- Peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Toxicity Criteria (NCI CTC)
- History of CNS metastasis, including epidural disease
- History of seizure disorder requiring active treatment and/or stroke
- History of HIV infection
- Platelet count ≤100,000/mm3
- Absolute neutrophil count (ANC) ≤1,500/mm3
- Hematocrit ≤30 percent
- Abnormal coagulation profile (PT, and/or INR, PTT)
- Creatinine clearance <60 mL/min or Serum creatinine >2.0 mg/dL
- AST or ALT >1.5 X ULN
- Bilirubin (total) >ULN
- Serum calcium ≥12.5 mg/dL
- Active serious infection not controlled by antibiotics
- Active angina pectoris or NY Heart Association Class III-IV heart disease
- Karnofsky Performance Status <60
- Life expectancy <6 months
- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2002
Study Registration Dates
First Submitted
January 21, 2003
First Submitted That Met QC Criteria
January 21, 2003
First Posted (Estimate)
January 22, 2003
Study Record Updates
Last Update Posted (Estimate)
March 1, 2007
Last Update Submitted That Met QC Criteria
February 28, 2007
Last Verified
February 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M59102-042
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
Clinical Trials on MLN2704 (DM1 conjugated monoclonal antibody MLN591)
-
Millennium Pharmaceuticals, Inc.CompletedProstatic NeoplasmsUnited States
-
George W. Sledge Jr.National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingStage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast AdenocarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditionsUnited States, Puerto Rico
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Approved for marketingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
University of WashingtonPfizerRecruitingAcute Myeloid LeukemiaUnited States
-
Shanghai Fosun Pharmaceutical Industrial Development...Recruiting
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Wilms Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Synovial Sarcoma | Pleuropulmonary BlastomaUnited States